∆9-tetrahydrocannabinol

Phase 2Small molecule

CCentre hospitalier de l'Université de Montréal (CHUM)

∆9-tetrahydrocannabinol is one of 3 small molecule programs targeting CBD. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CBDRecruiting

CBDPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in CBD

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Phase 2

3 2

Epidiolex

Jazz Pharmaceuticals

Phase 1

2 3

∆9-tetrahydrocannabinol

CCentre hospitalier de l'Université de Montréal (CHUM)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

CBD

NCT06099379

Clinical

Trials by Indication[1]

CBD1 trial

Modulation of THC Effects by CBD: a Dose-ranging Study

Recruiting·—·Phase 1/2·NCT06099379·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ∆9-tetrahydrocannabinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ∆9-tetrahydrocannabinol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ∆9-tetrahydrocannabinol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre hospitalier de l'Université de Montréal (CHUM) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCentre hospitalier de l'Université de Montréal (CHUM)

∆9-tetrahydrocannabinol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

CBD1 trial

References

Drug Info

Quick Facts

Related News